Page last updated: 2024-08-21

dronabinol and midazolam

dronabinol has been researched along with midazolam in 15 studies

Research

Studies (15)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's10 (66.67)29.6817
2010's4 (26.67)24.3611
2020's1 (6.67)2.80

Authors

AuthorsStudies
Topliss, JG; Yoshida, F1
Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY1
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1
Andricopulo, AD; Moda, TL; Montanari, CA1
Lombardo, F; Obach, RS; Waters, NJ1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
McMahon, LR2
Gehrig, AK; Heinrich, T; Mikus, G; Röder, CS1
Delatte, MS; Paronis, CA1
Becker, GL; France, CP; Gerak, LR; Li, JX; McMahon, LR1
Cohen, AF; de Kam, ML; Kleijn, HJ; Passier, PC; van Gerven, JM; Zuurman, L1
Bansal, S; Paine, MF; Spindle, TR; Thummel, KE; Unadkat, JD; Vandrey, R; Weerts, EM; Zamarripa, CA1

Reviews

1 review(s) available for dronabinol and midazolam

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Trials

1 trial(s) available for dronabinol and midazolam

ArticleYear
Pharmacodynamic and pharmacokinetic effects of the intravenous CB1 receptor agonist Org 26828 in healthy male volunteers.
    Journal of psychopharmacology (Oxford, England), 2010, Volume: 24, Issue:11

    Topics: Adult; Ambulatory Surgical Procedures; Conscious Sedation; Dose-Response Relationship, Drug; Dronabinol; Humans; Hypnotics and Sedatives; Infusions, Intravenous; Injections, Intravenous; Male; Midazolam; Receptor, Cannabinoid, CB1; Young Adult

2010

Other Studies

13 other study(ies) available for dronabinol and midazolam

ArticleYear
QSAR model for drug human oral bioavailability.
    Journal of medicinal chemistry, 2000, Jun-29, Volume: 43, Issue:13

    Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship

2000
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
    Journal of medicinal chemistry, 2004, Feb-26, Volume: 47, Issue:5

    Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution

2004
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004
Hologram QSAR model for the prediction of human oral bioavailability.
    Bioorganic & medicinal chemistry, 2007, Dec-15, Volume: 15, Issue:24

    Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship

2007
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
    Bioorganic & medicinal chemistry letters, 2010, Dec-15, Volume: 20, Issue:24

    Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility

2010
Characterization of cannabinoid agonists and apparent pA2 analysis of cannabinoid antagonists in rhesus monkeys discriminating Delta9-tetrahydrocannabinol.
    The Journal of pharmacology and experimental therapeutics, 2006, Volume: 319, Issue:3

    Topics: Analgesics, Opioid; Anesthetics, Dissociative; Anesthetics, Intravenous; Anesthetics, Local; Animals; Benzoxazines; Camphanes; Cannabinoid Receptor Agonists; Cannabinoid Receptor Antagonists; Cannabinoids; Cocaine; Cyclohexanols; Discrimination Learning; Dose-Response Relationship, Drug; Dronabinol; Female; Hallucinogens; Ketamine; Macaca mulatta; Male; Midazolam; Morphine; Morpholines; Naphthalenes; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2

2006
Discriminative stimulus effects of the cannabinoid CB1 antagonist SR 141716A in rhesus monkeys pretreated with Delta9-tetrahydrocannabinol.
    Psychopharmacology, 2006, Volume: 188, Issue:3

    Topics: Animals; Benzoxazines; Cannabinoids; Conditioning, Operant; Cyclohexanols; Discrimination Learning; Dose-Response Relationship, Drug; Dronabinol; Drug Interactions; Female; Hallucinogens; Humans; Injections, Intravenous; Injections, Subcutaneous; Ketamine; Macaca mulatta; Male; Midazolam; Morpholines; Naphthalenes; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Time Factors

2006
Misleading results of screening for illicit drugs during efavirenz treatment.
    AIDS (London, England), 2007, Jun-19, Volume: 21, Issue:10

    Topics: Alkynes; Benzodiazepines; Benzoxazines; Cyclopropanes; Dronabinol; Drug Administration Schedule; Humans; Immunoassay; Midazolam; Reverse Transcriptase Inhibitors; Substance Abuse Detection

2007
Evaluation of cannabinoid agonists using punished responding and midazolam discrimination procedures in squirrel monkeys.
    Psychopharmacology, 2008, Volume: 198, Issue:4

    Topics: Animals; Benzoxazines; Cannabinoids; Data Interpretation, Statistical; Discrimination Learning; Discrimination, Psychological; Dose-Response Relationship, Drug; Dronabinol; Food; gamma-Aminobutyric Acid; Hypnotics and Sedatives; Male; Midazolam; Morpholines; Naphthalenes; Punishment; Receptor, Cannabinoid, CB1; Saimiri

2008
Interactions between Delta(9)-tetrahydrocannabinol and mu opioid receptor agonists in rhesus monkeys: discrimination and antinociception.
    Psychopharmacology, 2008, Volume: 199, Issue:2

    Topics: Analgesics; Analgesics, Opioid; Animals; Data Interpretation, Statistical; Discrimination, Psychological; Dose-Response Relationship, Drug; Dronabinol; Drug Interactions; Female; Heroin; Hot Temperature; Hypnotics and Sedatives; Macaca mulatta; Male; Midazolam; Morphine; Morphine Dependence; Naltrexone; Narcotic Antagonists; Pain Measurement; Receptors, Opioid, mu; Substance Withdrawal Syndrome

2008
Evaluation of Cytochrome P450-Mediated Cannabinoid-Drug Interactions in Healthy Adult Participants.
    Clinical pharmacology and therapeutics, 2023, Volume: 114, Issue:3

    Topics: Adult; Caffeine; Cannabidiol; Cannabinoids; Cannabis; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dronabinol; Drug Interactions; Hallucinogens; Humans; Losartan; Midazolam; Omeprazole; Plant Extracts

2023